FDA Publishes Immunogenicity Guidelines For Biosimilar Insulins
Biosimilar Insulins Generally Will Not Need Comparative Clinical Immunogenicity Data
• By Michael Cipriano
The US FDA is proposing streamlining development of biosimilar/interchangeable insulins • Source: Shutterstock 
